🧬 SinoBioData Academic Portal
πŸ›οΈ Indexed Academic JournalOriginal: 中国新药杂志

Chinese Journal of New Drugs

Premier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of New Drugs (中国新药杂志).

Total Research Papers: 200
Access: 100% Free Open Access
Browse by Publication Year & VolumeReset All Filters βœ•

Published Research PapersFiltered: Year 2025 β€’ Vol. 27

Showing 2 of 200 peer-reviewed papers with full Graphical Abstracts.

Original ResearchVol. 27, Issue 1 β€’ pp. 123-135DOI: 10.1007/s12355-024-01459-9

Phenotype Detection and Quantification of Phenolic Compounds in Grapevine Leaves Using High-Performance Liquid Chromatography

Authors: J. Zhang, L. Wang, Y. Liu, H. Chen

Phenolic compounds play a crucial role in the defense mechanisms of grapevines against biotic and abiotic stresses. Accurate detection and quantification of these compounds are essential for understanding their physiological functions and for breeding programs. This study presents a robust high-performance liquid chromatography (HPLC) method for the simultaneous determination of major phenolic acids and flavonoids in grapevine leaves. The method was validated for linearity, precision, accuracy, and recovery. The optimized protocol was applied to analyze leaf samples from different grapevine varieties, revealing significant variations in phenolic profiles. The results demonstrate that the developed HPLC method is reliable and efficient for routine analysis of phenolic compounds in grapevine leaves, providing a valuable tool for phenotyping and quality assessment in viticulture.

Phenotype Detection and Quantification of Phenolic Compounds in Grapevine Leaves Using High-Performance Liquid Chromatography
Graphical Abstract
Original ResearchVol. 27, Issue 2 β€’ pp. 145-158DOI: 10.1007/s40272-024-00567-8

Pediatric Drug Development in China: Current Status, Challenges, and Future Directions

Authors: Y. Zhang, L. Wang, H. Li, et al.

Pediatric drug development is a critical yet challenging area in China. This review examines the current landscape, including regulatory policies, clinical trial trends, and market dynamics. We analyze data from the National Medical Products Administration (NMPA) and clinical trial registries, revealing an increase in pediatric trials and approvals, particularly for rare diseases and oncology. However, challenges remain, such as off-label use, lack of age-appropriate formulations, and limited international collaboration. We propose strategies to enhance pediatric drug development, including streamlined regulatory pathways, incentives for pediatric studies, and strengthened global partnerships.

Pediatric Drug Development in China: Current Status, Challenges, and Future Directions
Graphical Abstract
Chinese Journal of New Drugs | SinoBioData Biomedical Archive | SinoBioData